Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 15/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22094933 | 0.86 | MAPT (0.97) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3536564 | 0.86 | MAPT (0.97) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL29039490 | 0.85 | HPGD (0.63) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25855484 | 0.85 | HPGD (0.63) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL40059 | 0.85 | HPGD (0.68) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3837554 | 0.85 | HPGD (1.00) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3381562 | 0.85 | LMNA (0.97) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL21066338 | 0.85 | MAPT (0.73) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL10651251 | 0.85 | HPGD (0.68) | HPGDMAPTALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL12478410 | 0.85 | MAPT (0.73) | HPGDMAPTALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | HPGD 3117/4885MAPT 3151/4885ALDH1A1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.